MANKIND Mankind Pharma Q4 FY26 results (Jan–Mar 2026) and concall
Mankind Pharma reported a strong Q4 FY26 with 11.8% revenue growth and significant EBITDA margin expansion to 27.1%, driven by robust domestic performance and strategic advancements. While full-year PAT saw a slight decline due to acquisition-related costs, the company expressed confidence in regaining growth momentum and outlined ambitious targets for FY27, including double-digit top-line growth and improved margins. Strategic focus remains on specialty chronic therapies, R&D-led innovation, and disciplined capital allocation, including a new biotech facility.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 11.8%, net profit up 31.5% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 3,199 | 3,079 | 3,570 | 3,697 | 3,567 +12% | 3,443 +12% |
| EBITDA | 816 | 683 | 847 | 921 | 919 +13% | 930 +36% |
| Net profit | 385 | 425 | 445 | 520 | 414 +8% | 559 +32% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
